Back to Journals » Cancer Management and Research » Volume 12

miR-489-3p Inhibits Prostate Cancer Progression by Targeting DLX1 [Retraction]

Authors Bai P, Li W, Wan Z, Xiao Y, Xiao W, Wang X, Wu Z, Zhang K , Wang Y, Chen B, Xing J, Wang T

Received 1 December 2020

Accepted for publication 1 December 2020

Published 7 December 2020 Volume 2020:12 Pages 12581—12582


Bai P, Li W, Wan Z, et al. Cancer Manag Res. 2020;12:2719–2729.

At the request of the author, the Editor and Publisher of Cancer Management and Research wish to retract the published paper.

Following a review of their study the authors were unable to repeat the results described in the published paper for subsequent experiments. As a result, the authors can no longer confirm that overexpression of miR-489-3p was able to suppress luciferase activity by transfection with an miR-489 expression plasmid. The authors also found an error in Figure 6. The image used for Figure 6A Panel 22Rv1 miR-489-3p had been duplicated with the image used for Figure 6C 22Rv1 miR-489-3p+DLX1. In the interests of scientific integrity, the authors have determined it best to retract the published article.

The Editor has determined the findings of the paper are no longer valid and has agreed with the authors request to retract the article.

The author wished to apologise for this error.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

This retraction relates to this paper

Creative Commons License © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.